Exploring Emerging Data in NMIBC

Author(s):

Félix Guerrero-Ramos, MD, PhD, FEBU ,Srikala Sridhar, MD

Key Takeaways

BladderGATE trial explores frontline use of PD1+BCG, showing promise in bladder cancer treatment advancements.
Enfortamab vedotin and pembrolizumab combination is under investigation, potentially enhancing therapeutic efficacy.
Clinical complete response is a key endpoint, offering insights into treatment success and patient outcomes.
Circulating tumor DNA is emerging as a non-invasive biomarker, aiding in monitoring treatment response and disease progression.

Panelists discuss existing and upcoming data in non–muscle-invasive (NMIBC) bladder cancer treatment, including insights from the BladderGATE trial on frontline use of PD-1 inhibitors combined with BCG and the enfortamab vedotin plus pembrolizumab combination while also addressing the significance of clinical complete response as an end point and the potential role of circulating tumor DNA in future evaluations.

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

Now Viewing

EP: 9.Exploring Emerging Data in NMIBC

EP: 10.Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

What other data exists? What upcoming data are you excited about? * (bladdergate, First Results of the Phase Ib-II BladderGATE exploring frontline use of PD1+BCG etc.)
Enfortamab vedotin plus pembrolizumab combination
Please discuss clinical complete response as an end point for these trials. What about circulating tumor DNA?